基本信息
views: 22

Bio
Research in the Stauss lab focusses on T cell immunology, with a particular focus on the role of the T cell receptor (TCR) in the recognition of cancer antigens.
Research summary
Cancer is a major health problem worldwide with WHO projections predicting an increase in incidence by 57% from 14 million cases in 2012 to 22 million cases by 2032. We are interested in exploring the role of the immune system in tumour development, and whether novel forms of immunotherapy can be used to treat cancer.
The research of our group is focussed on T cell immunology, with a particular focus the role of the T cell receptor (TCR) in the recognition of cancer antigens. We were amongst the first to show that cytotoxic T cells can selectively attack cancer cells by recognising point mutations in transforming proteins expressed in tumours (J Exp Med. 1993; 177:1493). We have since developed strategies to isolate monoclonal TCR that are specific for tumour antigens, and we use these TCR for gene therapy to redirected the specificity of patient T cells and equip them with the ability to selectively recognize and attack cancer cells.
The use of TCR gene therapy to produce antigen-specific cytotoxic and helper T cells is one area of active research in our group. We also use TCR and chimeric antigen receptor (CAR) gene transfer to produce antigen-specific regulatory T cells. This provides the opportunity to achieve highly selective immune suppression and treat autoimmune conditions without the need for systemic immune suppression.
We use gene transfer technologies to direct the functional profile of therapeutic T cells. We have developed genetic switches to enhance or suppress the metabolic activity of T cells, and this promote effector function or memory formation. Transfer of genes encoding transcription factors is used to drive Th1, Th2 or Th17 differentiation of adoptively transferred T cells. We perform studies with human T cells in vitro, and in immunodeficient mice in vivo. Murine models are used for mechanistic studies and to test therapeutic interventions in appropriate disease models.
Research summary
Cancer is a major health problem worldwide with WHO projections predicting an increase in incidence by 57% from 14 million cases in 2012 to 22 million cases by 2032. We are interested in exploring the role of the immune system in tumour development, and whether novel forms of immunotherapy can be used to treat cancer.
The research of our group is focussed on T cell immunology, with a particular focus the role of the T cell receptor (TCR) in the recognition of cancer antigens. We were amongst the first to show that cytotoxic T cells can selectively attack cancer cells by recognising point mutations in transforming proteins expressed in tumours (J Exp Med. 1993; 177:1493). We have since developed strategies to isolate monoclonal TCR that are specific for tumour antigens, and we use these TCR for gene therapy to redirected the specificity of patient T cells and equip them with the ability to selectively recognize and attack cancer cells.
The use of TCR gene therapy to produce antigen-specific cytotoxic and helper T cells is one area of active research in our group. We also use TCR and chimeric antigen receptor (CAR) gene transfer to produce antigen-specific regulatory T cells. This provides the opportunity to achieve highly selective immune suppression and treat autoimmune conditions without the need for systemic immune suppression.
We use gene transfer technologies to direct the functional profile of therapeutic T cells. We have developed genetic switches to enhance or suppress the metabolic activity of T cells, and this promote effector function or memory formation. Transfer of genes encoding transcription factors is used to drive Th1, Th2 or Th17 differentiation of adoptively transferred T cells. We perform studies with human T cells in vitro, and in immunodeficient mice in vivo. Murine models are used for mechanistic studies and to test therapeutic interventions in appropriate disease models.
Research Interests
Papers共 342 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Francesca Emily Sillito,Angelika Holler, Aideen T O'Neill, Lauren A Callender, Sian M Henson,Hans Stauss,Ronjon Chakraverty
Bloodno. Supplement 1 (2024): 7196-7196
Yiya Zhong,Hans J. Stauss
Cellsno. 10 (2024)
FRONTIERS IN IMMUNOLOGY (2024)
Neurology Neuroimmunology & Neuroinflammationno. 5 (2023)
HUMAN GENE THERAPYno. 21-22 (2023): A30-A30
Cited0Views0Bibtex
0
0
A. Jamali, V. Riechert, S. Hein, P. Adams, E. Herrera-Carrillo,B. Berkhout,K. Cichutek,J. Hartmann,C. Buchholz, A. Holler,O. Preham, N. Clemo,H. Stauss,N. Egri, E. González, M. Naranjo
Human Gene Therapy (2023)
crossref(2023)
Cited0Views0Bibtex
0
0
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 342
#Citation: 12105
H-Index: 58
G-Index: 99
Sociability: 7
Diversity: 4
Activity: 23
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn